APA (7th ed.) Citation

SE, B., JJH, T., SW, v. D., MM, O., I, F., RD, C., . . . CL, Z. (2025). Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: A randomized phase 2 trial. Nature medicine, 31(12), 4055. https://doi.org/10.1038/s41591-025-03943-w

Chicago Style (17th ed.) Citation

SE, Breukers, et al. "Neoadjuvant Ipilimumab and Nivolumab in Resectable Cutaneous Squamous Cell Carcinoma: A Randomized Phase 2 Trial." Nature Medicine 31, no. 12 (2025): 4055. https://doi.org/10.1038/s41591-025-03943-w.

MLA (9th ed.) Citation

SE, Breukers, et al. "Neoadjuvant Ipilimumab and Nivolumab in Resectable Cutaneous Squamous Cell Carcinoma: A Randomized Phase 2 Trial." Nature Medicine, vol. 31, no. 12, 2025, p. 4055, https://doi.org/10.1038/s41591-025-03943-w.